



VANMA83.00-LARG

RECEIVED

JUN 13 2001

PATENT

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Communi, et al.	)	Group Art Unit 1646
Appl. No.	:	09/077,173	)	
Filed	:	November 12, 1998	)	I hereby certify that this correspondence and all
For	:	HUMAN PYRIMIDINE	)	marked attachments are being deposited with
		RECEPTOR	)	the United States Postal Service as first-class
Examiner	:	Murphy, J.	)	mail in an envelope addressed to: Assistant
			)	Commissioner for Patents, Washington, D.C.
			)	20231, on
			)	June 5, 2001
			)	(Date)
			)	<i>Samuel Hart</i>
			)	Daniel Hart, Registration No. 40,637

15/C  
J.g.  
6/13/01  
(NE)

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231  
ATTENTION BOX: AF

Dear Sir:

In response to the Office Action of December 5, 2000 (Paper No. 13), please amend the above-captioned patent application as follows:

IN THE CLAIMS

Please cancel Claims 81-83, 85-88, and 90.

Please amend the claims as follows:

70. (Amended) An isolated receptor which binds nucleotides, wherein said receptor has an amino acid sequence having more than 60% homology with the amino acid sequence shown in SEQ ID NO:2.

74. (Twice Amended) An isolated nucleic acid molecule encoding a receptor which binds nucleotides, wherein said receptor has an amino acid sequence having more than 60% homology with the DNA sequence shown in SEQ ID NO:1.

80. (Twice Amended) An antisense probe having a sequence fully complementary to an isolated nucleic acid molecule encoding a receptor which binds nucleotides, wherein said